Amendment to the License Agreement between Indivior Inc., Indivior U.K. Limited, and Aegis Therapeutics, LLC made November 2020, 2024

6.2 Prosecution and Maintenance of Opiant Patent Rights. Opiant shall have the sole right (but not the obligation), at its expense, to prepare, file, prosecute and maintain the OPIANT Patent Rights.

6.5.2 Paragraph IV Claims. Notwithstanding Section 6.5.6, Opiant shall have the right, at its sole discretion and expense, to institute, prosecute, defend, and control any patent infringement litigation suit based on a Paragraph IV certification (i.e., an ANDA patent infringement litigation involving a patent listed pursuant to 21 U.S.C. Section 355(a)(2)(A)(iv)) or any equivalent action outside the United States involving any Assigned Patent. If required or requested by Opiant, Aegis shall cooperate fully in such litigation as a third-party at its own expense. In the event that AEGIS is named in or becomes a party to such litigation, OPIANT shall pay for all expenses, including attorneys’ fees, incurred by AEGIS. Any recovery realized as a result of such litigation shall be first applied to litigation expenses incurred by OPIANT under this Section 6.5.2. Any remaining recovery realized from litigation brought pursuant to this Section 6.5.2 shall be treated as profits on sales of Products for purposes of determining Net Sales under this License Agreement, with AEGIS receiving the applicable royalty for purposes of Section 4.4 on such deemed Net Sales, and OPIANT receiving the remainder. For purposes of illustration, if the recovery under this Section 6.5.2 is $100 Million (U.S. $100,000,000), after reimbursement of any reasonable litigation expenses, and OPIANT’s gross margin for the Product as determined for the most-recent Calendar Quarter completed prior to the initial certification or infringing action was eighty percent

(80%), then the Net Sales would be deemed to be One Hundred Twenty-Five Million U.S. dollars ($125,000,000) and such amount would be included in the next royalty report pursuant to Section 4.5.

If to Aegis:

Aegis Therapeutics, LLC

3430 Carmel Mount Road

Suite 300

San Diego, CA 92121

Attn: Jenny Alonso

with a copy to (which alone shall not constitute notice):

DLA Piper US LLP

One Liberty Place

1650 Market Street, Suite 5000

Philadelphia, PA 19103

Attn: Raymond A. Miller

If to Indivior or Indivior UK:

Indivior, Inc.

10710 Midlothian Turnpike

Suite 125

North Chesterfield, Virginia, 23235

Attn: Chief Legal Officer

“Valid Claim” shall mean, on a country-by-country basis, either (a) a claim of an issued and unexpired patent in any of the Assigned Patents, which has not been held permanently revoked, unenforceable, or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable, or unappealed within the time allowed for appeal, or

which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise, or (b) a claim of a pending patent application in any of the Assigned Patents, which claim was filed in good faith and has not been abandoned or finally disallowed without the possibility of appeal or refiling of such application.

________________________________    Dated: __________________________

IN WITNESS WHEREOF, Aegis and Indivior have executed this Patent Assignment as of the date first written above.

IN WITNESS WHEREOF, Aegis and Indivior have executed this Patent Assignment as of the date first written above.